Loading organizations...
§ Private Profile · Herzliya, Israel
Smartzyme Biopharma is a company.
Smartzyme Biopharma has raised $4.0M across 1 funding round.
Key people at Smartzyme Biopharma.
Smartzyme Biopharma has raised $4.0M in total across 1 funding round.
Smartzyme Biopharma develops novel enzymes for medical applications, leveraging its proprietary Provolution protein engineering platform. This technology enables efficient design and creation of advanced proteins with tailored biological functions. The company focuses on enhancing diagnostic tools and therapeutic solutions, notably improving accuracy and performance in glucose monitoring systems for individuals managing diabetes.
The company was founded in November 2013 by Shilo Ben Zeev, CEO, and David Baram, Ph.D., CTO. Their foundational insight centered on revolutionizing enzyme functionality through advanced protein design. This expertise aimed to overcome limitations in existing biological tools, facilitating development of more effective enzymatic components for biotechnological uses.
Smartzyme Biopharma primarily serves the medical and biotechnology sectors, impacting patients requiring improved diagnostic accuracy, such as those with diabetes. Its long-term vision is to establish engineered proteins as a standard for high-performance biological components, continuously advancing enzyme-driven medical technologies to create effective global health solutions.
Key people at Smartzyme Biopharma.
Smartzyme Biopharma has raised $4.0M in total across 1 funding round.
Smartzyme Biopharma's investors include Nissim Darvish MD, DSc.
SmartZyme BioPharma is a life science company specializing in protein design and engineering for biopharmaceutical applications, primarily developing next-generation enzymes for improved glucose monitoring in diabetes management.[1][2][5] Its core PROVOLUTION™ platform enables the creation of stable, accurate proteins and enzymes, targeting continuous glucose monitoring (CGM) devices that are more affordable, easier to manufacture, and mediator-free to better serve diabetic patients while meeting regulatory standards.[1][2][4] The company focuses on solving key challenges in diabetes care, such as enhancing sensor performance and accessibility, with early efforts in metabolic diseases via spin-offs, though its main momentum remains in diabetes tech as of recent updates.[1]
Founded in 2013 and headquartered in New York, New York, SmartZyme emerged as a startup leveraging proprietary protein engineering to innovate in biopharma and medtech.[1][5] Key leadership included Christopher Shepard, Ph.D., who served as general manager and CEO, later becoming interim CEO of a 2018 spin-off.[1] A pivotal moment came in December 2018 when SmartZyme spun off its protein-based therapeutic platform into Carnot BioSciences, partnering with HemoShear Therapeutics on rare metabolic diseases, including enzyme targets for inborn deficiencies; this allowed SmartZyme to refocus on its flagship diabetes glucose-sensing enzyme.[1] Early traction built on integrating advanced enzymes into CGM devices, positioning it at the intersection of biotech and diabetes monitoring needs.[2][4]
SmartZyme rides the wave of precision biopharma and diabetes tech innovation, capitalizing on surging demand for advanced CGM amid rising global diabetes prevalence and a shift toward affordable, non-invasive monitoring.[1][2] Timing aligns with 2010s biotech advances in protein engineering, enabling mediator-free sensors that address manufacturing bottlenecks in a market dominated by players like Dexcom and Abbott, where cost and accuracy drive adoption.[1][4] Favorable forces include regulatory pushes for accessible diabetes tools and partnerships (e.g., HemoShear for metabolic spin-offs), influencing the ecosystem by accelerating enzyme tech transfer from research to devices and inspiring similar protein platforms in medtech.[1]
SmartZyme's path forward hinges on commercializing its diabetes enzyme for CGM partnerships, potentially expanding PROVOLUTION™ to other metabolic or diagnostic enzymes amid ongoing biotech funding cycles.[1][2] Trends like AI-enhanced protein design and wearable health tech will amplify its momentum, though limited recent news post-2018 spin-off suggests a need for updates on clinical progress or deals. Its influence could grow by enabling cheaper, ubiquitous glucose monitoring, bridging biopharma and patient care—echoing its founding promise of transformative diabetes solutions.[1][4]
Smartzyme Biopharma has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Other Equity in October 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 27, 2015 | $4M Venture Round | Nissim Darvish MD, DSC | — | Announced |
